Tumor-derived CK1α mutations enhance MDMX inhibition of p53

Area of Science:

• Molecular Biology
• Cancer Genetics
• Signal Transduction

Background:

• Somatic missense mutations in CSNK1A1, encoding casein kinase 1 alpha (CK1α), are identified in myelodysplastic syndromes (MDS) with del(5q) karyotype.
• CSNK1A1 haplo-insufficiency results from chromosomal deletion in MDS.
• CK1α mutations are infrequently found in various solid and hematopoietic tumors, with their functional impact largely unknown.

Purpose of the Study:

• To investigate the functional consequences of tumor-associated CSNK1A1 mutations.
• To determine how CK1α mutations affect its interaction with p53 pathway components and Wnt signaling.

Main Methods:

• Analysis of tumor-associated CK1α mutations localization within the protein structure.
• Functional assays assessing mutant CK1α binding to MDMX and p53.
• Measurement of p21 and β-catenin phosphorylation levels to evaluate p53 and Wnt pathway activity.

Main Results:

• Tumor-associated CK1α mutations (E98K, D140A) were found in the substrate-binding cleft.
• Mutants showed enhanced binding to MDMX, increased MDMX-p53 interaction, and greater suppression of p21 expression.
• Mutants exhibited reduced β-catenin phosphorylation, leading to enhanced Wnt signaling.

Conclusions:

• CK1α mutations confer gain-of-function by enhancing MDMX interaction and inhibiting p53.
• Mutations also cause partial loss-of-function in suppressing Wnt signaling.
• These alterations may drive myeloid progenitor expansion in del(5q) MDS and contribute to other tumor progressions.